“This first landmark economic model examines the continuum of definitive care in burns and can bring value to the burn community by estimating the likely economic impact of new treatments for burns,” said Pinar Bilir, IQVIA.
April 24, 2018 ARANZ Medical reports their Silhouette skin imaging and measuring solutions have powered more than 100 clinical trials since 2007, and are proving to be a reliable choice for companies undertaking multi-center clinical trials. The company reports...
RECELL Pivotal Trial in Third-Degree Burns Meets Co-Primary Endpoints and Shows Statistically Significant Reduction in Donor Skin Requirements
ReCell pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree) burns with the RECELL® Autologous Cell Harvesting Device achieved its co-primary endpoints, demonstrating a statistically significant reduction in donor skin requirements versus standard of care while achieving comparable definitive wound closure.
4/13/18: Two presentations at the American Burn Association Meeting highlight potential of RECELL to improve patient care in difficult-to-treat burns.
RECELL Data Demonstrating Statistically Significant Reduction in Donor Skin Requirements and Pain, Increased Patient Satisfaction and Improved Donor Scar Outcomes for Second-Degree Burn Patients
RECELL Device presentations include data from pivotal trial and health economic results showing 44 percent reduction in total treatment costs compared to standard of care.
4/3/18: New name better reflects breadth of products and long-term vision for growth.
Avita Medical Announces Submission of U.S. FDA Premarket Approval Application for the ReCell Device for Treatment of Burn Injuries
September 28, 2018 Avita Medical announced today that it has submitted to the Food & Drug Administration (FDA) a Pre-Market Approval (PMA) application for its ReCell Autologous Cell Harvesting Device for treatment of burn injuries. The company reports that...
LimbFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study
LimbFlow reports this clinical trial is the initial step towards a U.S. approval pathway for the LimFlow System.